Bulk Pharmaceutical API Sources for CYSVIEW KIT

Bulk Pharmaceutical API Sources for CYSVIEW KIT

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS016002051
Molport		MolPort-016-582-410
Debye Scientific Co., Ltd		DB-063352
MedChemexpress MCE		HY-16045
AbaChemScene		CS-5206
abcr GmbH		AB237745

cysview kit Bulk Active Pharmaceutical Ingredient (API) Sources

Last updated: February 19, 2026

This analysis identifies current and potential sources for the bulk active pharmaceutical ingredient (API) of cysview kit, Cyanine 7-conjugated to 5-aminolevulinic acid (ALA). The focus is on suppliers with demonstrated capability in producing ALA and conjugating it with Cyanine 7, alongside regulatory compliance and production scale.

What is the Active Pharmaceutical Ingredient (API) in cysview kit?

The API in cysview kit is a conjugate of 5-aminolevulinic acid (ALA) and Cyanine 7. Specifically, it is Cyanine 7-conjugated to 5-aminolevulinic acid. This conjugate is designed to be administered to patients. Upon administration, it is metabolized to protoporphyrin IX (PpIX), a photosensitizer. When exposed to specific wavelengths of blue light (400-410 nm), PpIX fluoresces red, allowing for the visualization of cancerous tissue.

Chemical Structure and Properties

• 5-Aminolevulinic Acid (ALA): A naturally occurring molecule involved in porphyrin synthesis. It is a small molecule with a molecular weight of approximately 147.13 g/mol.
• Cyanine 7 (Cy7): A cyanine dye that absorbs and emits light in the near-infrared (NIR) spectrum. It is a larger, fluorescent molecule.
• Conjugate: The covalent linkage of ALA to Cyanine 7. The precise linkage and stoichiometry are critical for the drug's efficacy and pharmacokinetics. The specific structure of the cysview kit API is proprietary but involves a functionalization of ALA to attach it to the Cy7 moiety.

Who are the Key API Suppliers?

The supply chain for cysview kit API involves two primary components: the synthesis of 5-aminolevulinic acid (ALA) and the synthesis of Cyanine 7, followed by their conjugation. While specific manufacturers of the final conjugate for cysview kit are often proprietary, companies specializing in ALA synthesis and custom conjugation services are key potential suppliers.

Established ALA Manufacturers

5-Aminolevulinic acid (ALA) is produced by several chemical manufacturers globally. These companies typically supply ALA for various applications, including agriculture and pharmaceuticals.

• Key Producers of ALA:
  • Nippon Chemical Industrial Co., Ltd. (Japan): A significant producer of ALA, often supplying it for pharmaceutical applications. They have established manufacturing processes and regulatory compliance.
  • Shandong Xinhua Pharmaceutical Co., Ltd. (China): A large-scale pharmaceutical manufacturer that includes ALA in its product portfolio. Their production capacity is substantial.
  • Hubei Biocause Pharmaceutical Co., Ltd. (China): Another prominent Chinese manufacturer of pharmaceutical ingredients, including ALA.

Cyanine Dye and Conjugation Specialists

The synthesis of Cyanine 7 and its conjugation to ALA requires specialized expertise in organic synthesis and fluorescent dye chemistry. These companies often operate as contract manufacturing organizations (CMOs) or custom synthesis providers.

• Potential Conjugation Service Providers:
  • Thermo Fisher Scientific (USA): Through its Invitrogen brand, Thermo Fisher Scientific offers a wide range of fluorescent dyes, including cyanine dyes, and custom conjugation services. They possess expertise in linking various molecules to fluorescent tags.
  • Biotium, Inc. (USA): Biotium specializes in fluorescent probes and reagents, including cyanine dyes and kits for bioconjugation. They have a strong research and development arm.
  • Advanced Bio-Products (USA): This company provides custom synthesis of peptides, proteins, and fluorescent labels, including the conjugation of fluorescent dyes to biomolecules.
  • Cell Signaling Technology, Inc. (USA): While primarily known for antibodies, CST also offers reagents and services that can include custom dye conjugation for research and development purposes.

Note: The specific supplier(s) of the proprietary conjugate used in cysview kit are not publicly disclosed by the brand holder. However, the above companies represent entities with the technical capabilities to produce the constituent parts and perform the necessary conjugation.

What are the Regulatory Considerations for API Sourcing?

Sourcing bulk API for a pharmaceutical product like cysview kit requires stringent adherence to regulatory standards to ensure product safety, efficacy, and consistency.

Good Manufacturing Practices (GMP)

• Requirement: API manufacturers must comply with current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
• Audits: Facilities and processes are subject to regular inspections and audits by regulatory authorities and the drug product manufacturer.
• Documentation: Comprehensive documentation, including batch records, validation reports, and Certificates of Analysis (CoA), is mandatory.

Drug Master Files (DMFs)

• Purpose: API manufacturers often submit Drug Master Files (DMFs) to regulatory agencies. A DMF contains detailed information about the manufacturing, processing, packaging, and storing of the API.
• Confidentiality: DMFs are confidential documents, but the drug product manufacturer can reference them in their marketing authorization applications, allowing regulatory agencies to review the API information without public disclosure of the manufacturer's proprietary data.
• Types:
  • Type II DMF (FDA): Pertains to drug substance, intermediates, and materials used in their manufacture, or excipients.

Quality Control and Testing

• Specifications: API must meet predefined specifications for identity, purity, strength, and quality. This includes testing for impurities, residual solvents, and physical characteristics.
• Analytical Methods: Validated analytical methods, such as High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR) spectroscopy, are used for testing.
• Stability Studies: API must undergo stability testing to determine its shelf life under specified storage conditions.

Supply Chain Security and Traceability

• Counterfeit Prevention: Robust measures are required to prevent the introduction of counterfeit or substandard APIs into the supply chain.
• Traceability: The entire supply chain, from raw material sourcing to the final API batch, must be traceable.

What is the Production Scale and Capacity?

The production scale for the cysview kit API depends on the market demand for the final drug product. Manufacturers must be able to scale production to meet these demands while maintaining quality.

ALA Production Capacity

• Global Capacity: Major ALA manufacturers, particularly those in China and Japan, have significant production capacities, often in the multi-ton range per year. This capacity is generally sufficient for pharmaceutical demand.
• Scalability: Existing ALA production lines are typically designed for scalability, allowing for increases in output based on demand.

Cyanine 7 and Conjugation Capacity

• Specialized Production: Cyanine dye synthesis and conjugation are more specialized processes. The capacity for these activities is often more limited compared to bulk chemical production.
• Custom Synthesis: Companies offering custom conjugation services typically operate on a project-by-project basis, scaling their operations based on client needs. Production volumes can range from grams to kilograms, depending on the complexity and demand.
• Lead Times: The lead time for custom-synthesized conjugated APIs can range from several weeks to months, depending on the intricacy of the synthesis and the required scale.

Considerations for cysview kit

The demand for cysview kit API is directly tied to its approved indications and market penetration. For a niche diagnostic agent, the required API volume might be in the kilograms to tens of kilograms per year range. However, if the drug receives expanded indications or significant market adoption, the demand could increase substantially, requiring manufacturers to scale up their conjugation processes.

What are Potential Risks and Mitigation Strategies in API Sourcing?

Sourcing bulk API for pharmaceuticals involves inherent risks that must be managed to ensure an uninterrupted and high-quality supply.

Supply Chain Disruptions

• Causes: Geopolitical instability, natural disasters, regulatory changes, single-source dependency, and unexpected demand surges can disrupt the supply chain.
• Mitigation:
  • Dual Sourcing: Qualify and maintain relationships with at least two independent API manufacturers for critical components (ALA and conjugation services).
  • Inventory Management: Maintain adequate buffer stock of the API and key raw materials to cover potential short-term disruptions.
  • Geographic Diversification: Source from manufacturers located in different geographic regions to reduce the impact of regional-specific events.

Quality Control Failures

• Causes: Deviations from GMP, inadequate testing, human error, or process drift can lead to out-of-specification API.
• Mitigation:
  • Robust Supplier Qualification: Implement a rigorous supplier qualification program that includes on-site audits, review of quality systems, and assessment of regulatory history.
  • Incoming Quality Control (IQC): Conduct thorough testing of every incoming batch of API to confirm it meets all specifications.
  • Regular Audits: Perform periodic audits of qualified suppliers to ensure ongoing compliance.

Intellectual Property (IP) and Regulatory Compliance Issues

• Causes: Patent infringement, data integrity issues, or failure to maintain regulatory filings can halt production or market access.
• Mitigation:
  • IP Due Diligence: Conduct thorough freedom-to-operate analyses and patent landscape reviews for both ALA synthesis and conjugation processes.
  • Regulatory Monitoring: Stay abreast of evolving regulatory requirements in all target markets.
  • Contractual Agreements: Ensure robust contracts with suppliers that clearly define IP ownership, confidentiality, and regulatory compliance responsibilities.

Cost Volatility

• Causes: Fluctuations in raw material costs, energy prices, labor, and currency exchange rates can impact API pricing.
• Mitigation:
  • Long-Term Contracts: Negotiate long-term supply agreements with fixed or capped pricing for key raw materials and API.
  • Hedging Strategies: Employ financial instruments to hedge against currency fluctuations where appropriate.
  • Process Optimization: Work with suppliers to identify opportunities for cost reduction through process optimization and efficiency improvements.

Key Takeaways

• The API for cysview kit is a Cyanine 7-conjugated 5-aminolevulinic acid (ALA).
• Key suppliers for ALA are established pharmaceutical ingredient manufacturers in Japan and China.
• Cyanine dye synthesis and conjugation require specialized CMOs and custom synthesis providers, with major reagent companies offering such services.
• All API sourcing must comply with stringent cGMP regulations, supported by DMFs and rigorous quality control.
• Production scale for ALA is typically high, while conjugation capacity is more specialized and project-driven.
• Mitigation strategies for supply chain disruptions, quality failures, IP issues, and cost volatility include dual sourcing, rigorous supplier qualification, buffer inventory, and long-term contracts.

Frequently Asked Questions

What is the difference between ALA and the cysview kit API?

ALA is the precursor molecule, while the cysview kit API is a conjugate of ALA with Cyanine 7. The conjugation enhances its fluorescent properties and targeting for diagnostic imaging.

Can standard ALA suppliers also produce the Cyanine 7 conjugate?

No, standard ALA suppliers typically produce ALA. The synthesis of Cyanine 7 and its subsequent conjugation to ALA require specialized expertise in fluorescent dye chemistry and bioconjugation, which is usually performed by different entities, often custom synthesis providers.

What regulatory pathways are involved in qualifying an API supplier for cysview kit?

Qualification involves rigorous adherence to cGMP, submission of DMFs, successful regulatory audits, and comprehensive quality agreements between the drug product manufacturer and the API supplier.

How does the demand for cysview kit impact API production scale?

The market demand for cysview kit directly influences the required production scale. For niche diagnostic agents, volumes may be in the kilogram range, but expanded indications could necessitate scaling up conjugation processes to multi-kilogram or ton levels.

What are the primary challenges in ensuring a consistent supply of the Cyanine 7 conjugate?

Challenges include the specialized nature of Cyanine dye synthesis, the complexity of conjugation chemistry, potential single-source dependency for specific dye precursors, and the need for consistent quality control in these intricate processes.